Alkermes plc logo
Alkermes plc ALKS
$ 28.52 0.11%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

Alkermes plc Income Statement 2011-2025 | ALKS

Annual Income Statement Alkermes plc

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.56 B 4.88 B 4.61 B 3.74 B 3.17 B 2.74 B 5.09 B 8.79 B 7.92 B 4.78 B 10.5 B 4.2 B 1.98 B 1.38 B

Shares

165 M 166 M 164 M 161 M 159 M 157 M 155 M 153 M 151 M 149 M 145 M 137 M 115 M 95.6 M

Historical Prices

33.6 29.4 28.2 23.3 19.9 20.4 29.5 54.7 55.6 79.4 58.6 40.7 18.5 17.4

Net Income

367 M 356 M -158 M -48.2 M -111 M -197 M -139 M -158 M -208 M -227 M -30.1 M 25 M -114 M -45.5 M

Revenue

1.56 B 1.66 B 1.11 B 1.17 B 1.04 B 1.17 B 1.09 B 903 M 746 M 628 M 619 M 576 M 390 M 187 M

Cost of Revenue

245 M 253 M 218 M 197 M 178 M 180 M 176 M 155 M 132 M - - - - -

Gross Profit

- - - - - 991 M 918 M 749 M 614 M 489 M 443 M 405 M 262 M 134 M

Operating Income

421 M 414 M -6.09 M 97.7 M -112 M -175 M -99.1 M -148 M -209 M -224 M -87.1 M 34.5 M -88.3 M -45.6 M

Interest Expense

3.24 M -425 K 2.12 M 11.2 M 8.66 M 13.6 M 15.4 M 12 M 14.9 M 13.2 M 13.4 M 49 M 28.1 M 3.3 M

EBITDA

449 M 489 M 71.8 M 176 M -30.6 M -95.1 M 4.53 M -49.4 M -114 M -139 M 10.9 M 156 M 5.4 M -37 M

Operating Expenses

- - - - - 640 M 592 M 484 M 435 M 369 M 258 M 168 M 351 M 180 M

General and Administrative Expenses

199 M 200 M 199 M 550 M 539 M 599 M 526 M 422 M 374 M 312 M 200 M 126 M 138 M 82.8 M

All numbers in USD currency

Quarterly Income Statement Alkermes plc

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

165 M 163 M 162 M 163 M 168 M 168 M 167 M 167 M 166 M 165 M 164 M 164 M 164 M 162 M 162 M 161 M 161 M 160 M 159 M 159 M 159 M 158 M 158 M 157 M 157 M 156 M 156 M 155 M 155 M 154 M 154 M 154 M 153 M 153 M 152 M 152 M 151 M 151 M 151 M 150 M 149 M 148 M 148 M 146 M 145 M 143 M 138 M 136 M 135 M 133 M 132 M 131 M 131 M 130 M 130 M 110 M 99.6 M 95.7 M

Net Income

87.1 M 22.5 M - 92.4 M 91.4 M 36.8 M - 47.8 M 237 M -41.8 M - -64 M -30.1 M -35.9 M - -29 M 2.36 M -22.4 M - -134 K -29.4 M -38.7 M - -52.9 M -42 M -96.4 M - -34.4 M -32.6 M -62.5 M - -36.3 M -112 M -68.9 M - -187 M -125 M -77.4 M - -81 M -46.1 M -30.7 M - -40 M 3.74 M -24.4 M - -7.76 M 7.33 M 3 M 16.3 M -16.7 M 5.73 M - -14.8 M -22.3 M -35.5 M -

Revenue

391 M 307 M - 378 M 399 M 350 M - 381 M 617 M 288 M - 252 M 276 M 279 M - 294 M 304 M 251 M - 265 M 248 M 246 M - 255 M 280 M 223 M - 249 M 305 M 225 M - 217 M 219 M 192 M - 180 M 195 M 157 M - 153 M 151 M 161 M - 160 M 153 M 130 M - 140 M 139 M 163 M 136 M 124 M 276 M - 126 M 260 M 134 M -

Cost of Revenue

49.5 M 49.2 M - 63.1 M 61.5 M 58.6 M - 61.5 M 63.2 M 58.2 M - 50.6 M 58.4 M 55.2 M - 49.6 M 53.1 M 41 M - 43.1 M 45.1 M 47.2 M - 42.3 M 46.2 M 45.4 M - 39.4 M 43.4 M 44.5 M - 36.1 M 39.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

93 M 13.8 M - 105 M 110 M 43.3 M - 89.2 M 281 M -11 M - -60.6 M -34.5 M -26.6 M - -19.7 M 4.42 M -16.4 M - -10.7 M -33.7 M -37.4 M - -53.6 M -35.9 M -76 M - -37.2 M -102 K -61.9 M - -38.4 M -44.5 M -70.9 M - -61.1 M -47.1 M -76.9 M - -77.4 M -52.5 M -27.3 M - -32.7 M -22.8 M -15.9 M - -3.88 M 13.5 M 19 M 25.3 M 5.42 M 37.6 M - -4.97 M -30.6 M -25.6 M -

Interest Expense

- 1.56 M - 558 K 5.95 M 182 K - 149 K 5.68 M 5.29 M - 3.55 M 2.37 M 2.35 M - 2.44 M 2.41 M 3.97 M - 1.81 M 2.12 M 2.86 M - 3.38 M 3.52 M 3.5 M - 3.35 M 3.13 M 5.49 M - 3.13 M 2.92 M 2.76 M - 3.38 M 3.32 M 3.3 M - 3.32 M 3.32 M 3.29 M - 3.36 M 3.38 M 3.36 M - 3.48 M 3.47 M 11.5 M 4.7 M 22.6 M 32.8 M - 10.5 M 18 M 7.56 M -

EBITDA

- 21.2 M - 105 M 110 M 51.4 M - 98.2 M 290 M 7.74 M - -51.5 M -25.4 M -7.39 M - 37.9 M 13.9 M 3.21 M - 50.9 M 7.28 M -16.8 M - 6.28 M 3.63 M -56.4 M - 40.6 M 51.4 M -36.2 M - 34.9 M 3.76 M -47.1 M - 8.48 M -1.33 M -54.2 M - -13.6 M -9.41 M -4.82 M - 40 M 24.7 M 6.66 M - 61.8 M 37.3 M 37.3 M 35.8 M 16 M 74.4 M - 6.93 M -3.36 M -19.3 M -

General and Administrative Expenses

49.7 M 48.8 M - 150 M 48.4 M 54.1 M - 156 M 196 M 168 M - 153 M 150 M 145 M - 136 M 139 M 125 M - 128 M 132 M 133 M - 149 M 155 M 141 M - 129 M 138 M 118 M - 99.6 M 109 M 102 M - 91.1 M 96.1 M 89.7 M - 89.5 M 71.5 M 63 M - 51.9 M 50.7 M 42.6 M - 39.5 M 32.9 M 34.7 M 29.9 M 31.4 M 61.2 M - 35.5 M 103 M 67.7 M -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Alkermes plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.79 2.35 % $ 795 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.04 4.83 % $ 235 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.17 4.46 % $ 6.38 M chinaChina
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.93 -8.81 % $ 257 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BioVie BioVie
BIVI
$ 1.27 -3.05 % $ 1.88 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.81 1.71 % $ 5 B danmarkDanmark
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.18 -25.03 % $ 392 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.37 2.06 % $ 814 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 0.16 % $ 7.46 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.03 0.95 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.81 1.36 % $ 1.3 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.48 0.96 % $ 139 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 83.59 1.95 % $ 8.63 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 591.15 0.02 % $ 44.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.53 -0.39 % $ 15.9 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.45 0.91 % $ 2.9 B usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.45 0.34 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.83 0.94 % $ 1.73 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA